Credit Suisse analyst Vamil Divan maintained a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT) on June 11 and set a price target of $47. The company’s shares closed yesterday at $30.60.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.5% and a 44.7% success rate. Divan covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Bristol Myers.
Currently, the analyst consensus on Aimmune Therapeutics is Strong Buy and the average price target is $56.60, representing an 85.0% upside.
In a report issued on May 30, Wedbush also reiterated a Buy rating on the stock with a $72 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42 and a one-year low of $16.25. Currently, Aimmune Therapeutics has an average volume of 608K.
Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AIMT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
